Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Has anyone ever been to Algernons head office?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(27)
•••
Post by 294everon Mar 20, 2021 12:04pm
296 Views
Post# 32844998

Has anyone ever been to Algernons head office?

Has anyone ever been to Algernons head office?

Just wondering how big suite #915 could be?

Seems like a bit of a clown car in there.

Businesses currently listed to this address

Westward Advisors Ltd.
First Responder Technologies Inc.
Algernon Pharmaceuticals Inc.
Beyond Medical Technologies inc. (Micron Waste)
Bull Run Capital Inc.
Sadhra and Chow LLP
Hybrid Minerals Inc
Karam Minerals inc

Makes you scratch your head and wonder how connected they are and who's in the middle of it all? Anybody got any idea/input? Just curious is all. With all the missed/slow enrolment dates and delays I wonder if it has anything to do with the CEO likely in all reality not having his own desk. Something weird going on. I don't like it.





 

External Website. Opens New Window

 

 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities